Labiana Health

Labiana Health EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Labiana Health (LAB.MC) as of Nov 19, 2026 is 10.34. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 7.76 — a change of 33.26% (higher).

EV/EBITDA

10.34

YoY

33.26%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Labiana Health is 2025 10.34 . EV/EBITDA (Enterprise Value to EBITDA) of Labiana Health was 2024 7.76 . It decreases by 33.26% higher compared to the previous year.

The Labiana Health EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
18.55 EUR
Jan 1, 2019
17.67 EUR
Jan 1, 2020
8.54 EUR
Jan 1, 2021
12.47 EUR
Jan 1, 2022
-41.31 EUR
Jan 1, 2023
23.27 EUR
Jan 1, 2024
7.76 EUR
Jan 1, 2025
10.34 EUR
The Labiana Health EV/EBITDA history
YEAREV/EBITDAYoY
10.34+33.26%
7.76-66.66%
23.27-156.33%
-41.31-431.19%
12.47+45.98%
8.54-51.66%
17.67-4.72%
18.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

EV/EBITDA (Enterprise Value to EBITDA) of Labiana Health is 10.34 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Labiana Health changed from 7.76 to 10.34, representing a 33.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Labiana Health since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Labiana Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Labiana Health

All Key Metrics — Labiana Health